Pharmacology of heart failure: From basic science to novel therapies

Pharmacology and Therapeutics

Volumn 166, Issue , 2016, Pages 136-149

  Lother, Achim ^a   Hein, Lutz ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Angiotensin receptor and neprilysin inhibitor; Epigenetics; Heart failure; Ivabradine; Mineralocorticoid receptor; Omecamtiv mecarbil

Indexed keywords

ALDOSTERONE; ANGIOTENSIN RECEPTOR; CALCIUM; CYCLIC GMP; GUANYLATE CYCLASE ACTIVATOR; HISTONE DEACETYLASE; HYPERPOLARIZATION ACTIVATED CYCLIC NUCLEOTIDE GATED CHANNEL; INTERLEUKIN 1BETA; IVABRADINE; LEVOSIMENDAN; MEMBRANE METALLOENDOPEPTIDASE; MICRORNA; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; NATRIURETIC FACTOR; OMECAMTIV MECARBIL; PHOSPHODIESTERASE V INHIBITOR; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT; GUANYLATE CYCLASE; MYOSIN; SACUBITRIL PLUS VALSARTAN; TETRAZOLE DERIVATIVE;

ARTICLE; CARDIAC MUSCLE CELL; CARDIOVASCULAR MORTALITY; DNA METHYLATION; ENZYME DEGRADATION; GENE TRANSFER; HEART FAILURE; HEART RATE; HUMAN; INFLAMMATION; MEDICAL SOCIETY; MORBIDITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SARCOMERE; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; BENZAZEPINES; CARDIOVASCULAR AGENTS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; GUANYLATE CYCLASE; HEART FAILURE; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MYOSINS; NEPRILYSIN; PRACTICE GUIDELINES AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 84979765673     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2016.07.004     Document Type: Article

References (205)

1. Abbate, A., Van Tassell, B.W., Seropian, I.M., Toldo, S., Robati, R., Varma, A.,.. Dinarello, C.A., Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. Eur J Heart Fail 12 (2010), 319–322.
2. Abbate, A., Kontos, M.C., Abouzaki, N.A., Melchior, R.D., Thomas, C., Van Tassell, B.W.,.. Biondi-Zoccai, G., Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). Am J Cardiol 115 (2015), 288–292.
3. Aguirre, A., Montserrat, N., Zacchigna, S., Nivet, E., Hishida, T., Krause, M.N.,.. Izpisua Belmonte, J.C., In vivo activation of a conserved microRNA program induces mammalian heart regeneration. Cell Stem Cell 15 (2014), 589–604.
4. Amar, L., Azizi, M., Menard, J., Peyrard, S., Watson, C., Plouin, P.F., Aldosterone synthase inhibition with LCI699: A proof-of-concept study in patients with primary aldosteronism. Hypertension 56 (2010), 831–838.
5. Ameres, S.L., Zamore, P.D., Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol 14 (2013), 475–488.
6. Anand, P., Brown, J.D., Lin, C.Y., Qi, J., Zhang, R., Artero, P.C.,.. Haldar, S.M., BET bromodomains mediate transcriptional pause release in heart failure. Cell 154 (2013), 569–582.
7. Antos, C.L., McKinsey, T.A., Dreitz, M., Hollingsworth, L.M., Zhang, C.L., Schreiber, K.,.. Olson, E.N., Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem 278 (2003), 28930–28937.
8. Backs, J., Song, K., Bezprozvannaya, S., Chang, S., Olson, E.N., CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J Clin Invest 116 (2006), 1853–1864.
9. Backs, J., Backs, T., Neef, S., Kreusser, M.M., Lehmann, L.H., Patrick, D.M.,.. Olson, E.N., The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci U S A 106 (2009), 2342–2347.
10. Bakris, G.L., Agarwal, R., Chan, J.C., Cooper, M.E., Gansevoort, R.T., Haller, H.,.. Ruilope, L.M., Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial. JAMA 314 (2015), 884–894.
11. Bang, C., Batkai, S., Dangwal, S., Gupta, S.K., Foinquinos, A., Holzmann, A.,.. Thum, T., Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest 124 (2014), 2136–2146.
12. Barfacker, L., Kuhl, A., Hillisch, A., Grosser, R., Figueroa-Perez, S., Heckroth, H.,.. Kolkhof, P., Discovery of BAY 94-8862: A nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 7 (2012), 1385–1403.
13. Baruscotti, M., Bucchi, A., Difrancesco, D., Physiology and pharmacology of the cardiac pacemaker (“funny”) current. Pharmacol Ther 107 (2005), 59–79.
14. Bers, D.M., Cardiac excitation-contraction coupling. Nature 415 (2002), 198–205.
15. Bois, P., Bescond, J., Renaudon, B., Lenfant, J., Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 118 (1996), 1051–1057.
16. Borlaug, B.A., Lewis, G.D., McNulty, S.E., Semigran, M.J., LeWinter, M., Chen, H.,.. Redfield, M.M., Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction. Circ Heart Fail 8 (2015), 533–541.
17. Braunwald, E., Biomarkers in heart failure. N Engl J Med 358 (2008), 2148–2159.
18. Braunwald, E., The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J Am Coll Cardiol 65 (2015), 1029–1041.
19. Brinks, H., Rohde, D., Voelkers, M., Qiu, G., Pleger, S.T., Herzog, N.,.. Most, P., S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. J Am Coll Cardiol 58 (2011), 966–973.
20. Bronnum, H., Andersen, D.C., Schneider, M., Sandberg, M.B., Eskildsen, T., Nielsen, S.B.,.. Sheikh, S.P., miR-21 promotes fibrogenic epithelial-to-mesenchymal transition of epicardial mesothelial cells involving Programmed Cell Death 4 and Sprouty-1. PLoS One, 8, 2013, e56280.
21. Buglioni, A., Burnett, J.C. Jr., New pharmacological strategies to increase cGMP. Annu Rev Med 67 (2016), 229–243.
22. Burchfield, J.S., Xie, M., Hill, J.A., Pathological ventricular remodeling: Mechanisms: Part 1 of 2. Circulation 128 (2013), 388–400.
23. Callis, T.E., Pandya, K., Seok, H.Y., Tang, R.H., Tatsuguchi, M., Huang, Z.P.,.. Wang, D.Z., MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 119 (2009), 2772–2786.
24. Cao, D.J., Wang, Z.V., Battiprolu, P.K., Jiang, N., Morales, C.R., Kong, Y.,.. Hill, J.A., Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc Natl Acad Sci U S A 108 (2011), 4123–4128.
25. Cao, S., Zeng, Z., Wang, X., Bin, J., Xu, D., Liao, Y., Pravastatin slows the progression of heart failure by inhibiting the c-Jun N-terminal kinase-mediated intrinsic apoptotic signaling pathway. Mol Med Rep 8 (2013), 1163–1168.
26. Chung, E.S., Packer, M., Lo, K.H., Fasanmade, A.A., Willerson, J.T., Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 (2003), 3133–3140.
27. CIBIS-II, The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 353 (1999), 9–13.
28. Cleland, J.G., Teerlink, J.R., Senior, R., Nifontov, E.M., Mc Murray, J.J., Lang, C.C.,.. Malik, F.I., The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: A double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 378 (2011), 676–683.
29. CONSENSUS, Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316 (1987), 1429–1435.
30. Cullington, D., Goode, K.M., Clark, A.L., Cleland, J.G., Heart rate achieved or beta-blocker dose in patients with chronic heart failure: Which is the better target?. Eur J Heart Fail 14 (2012), 737–747.
31. Degen, C.V., Bishu, K., Zakeri, R., Ogut, O., Redfield, M.M., Brozovich, F.V., The emperor's new clothes: PDE5 and the heart. PLoS One, 10, 2015, e0118664.
32. Deiss, K., Kisker, C., Lohse, M.J., Lorenz, K., Raf kinase inhibitor protein (RKIP) dimer formation controls its target switch from Raf1 to G protein-coupled receptor kinase (GRK) 2. J Biol Chem 287 (2012), 23407–23417.
33. del Monte, F., Williams, E., Lebeche, D., Schmidt, U., Rosenzweig, A., Gwathmey, J.K.,.. Hajjar, R.J., Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2 +)-ATPase in a rat model of heart failure. Circulation 104 (2001), 1424–1429.
34. del Monte, F., Harding, S.E., Dec, G.W., Gwathmey, J.K., Hajjar, R.J., Targeting phospholamban by gene transfer in human heart failure. Circulation 105 (2002), 904–907.
35. Delgado-Olguin, P., Huang, Y., Li, X., Christodoulou, D., Seidman, C.E., Seidman, J.G.,.. Bruneau, B.G., Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for postnatal cardiac homeostasis. Nat Genet 44 (2012), 343–347.
36. Diaz, A., Bourassa, M.G., Guertin, M.C., Tardif, J.C., Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 26 (2005), 967–974.
37. Ding, B., Abe, J., Wei, H., Huang, Q., Walsh, R.A., Molina, C.A.,.. Yan, C., Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: Implication in heart failure. Circulation 111 (2005), 2469–2476.
38. Ding, J., Chen, J., Wang, Y., Kataoka, M., Ma, L., Zhou, P.,.. Wang, D.Z., Trbp regulates heart function through microRNA-mediated Sox6 repression. Nat Genet 47 (2015), 776–783.
39. Dirkx, E., Gladka, M.M., Philippen, L.E., Armand, A.S., Kinet, V., Leptidis, S.,.. De Windt, L.J., Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure. Nat Cell Biol 15 (2013), 1282–1293.
40. Dong, S., Ma, W., Hao, B., Hu, F., Yan, L., Yan, X.,.. Wang, Z., microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2. Int J Clin Exp Pathol 7 (2014), 565–574.
41. Dubin, R.F., Shah, S.J., Soluble guanylate cyclase stimulators: A novel treatment option for heart failure associated with cardiorenal syndromes?. Curr Heart Fail Rep. 13 (2016), 132–139.
42. Edwards, B.S., Zimmerman, R.S., Schwab, T.R., Heublein, D.M., Burnett, J.C. Jr., Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res 62 (1988), 191–195.
43. Eisner, D., Caldwell, J., Trafford, A., Sarcoplasmic reticulum Ca-ATPase and heart failure 20 years later. Circ Res 113 (2013), 958–961.
44. Epelman, S., Lavine, K.J., Beaudin, A.E., Sojka, D.K., Carrero, J.A., Calderon, B.,.. Mann, D.L., Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation. Immunity 40 (2014), 91–104.
45. Erdmann, E., Semigran, M.J., Nieminen, M.S., Gheorghiade, M., Agrawal, R., Mitrovic, V., Mebazaa, A., Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J 34 (2013), 57–67.
46. Fagart, J., Hillisch, A., Huyet, J., Barfacker, L., Fay, M., Pleiss, U.,.. Kolkhof, P., A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule. J Biol Chem 285 (2010), 29932–29940.
47. Falkenberg, K.J., Johnstone, R.W., Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 13 (2014), 673–691.
48. Faresse, N., Ruffieux-Daidie, D., Salamin, M., Gomez-Sanchez, C.E., Staub, O., Mineralocorticoid receptor degradation is promoted by Hsp90 inhibition and the ubiquitin-protein ligase CHIP. Am J Physiol Ren Physiol 299 (2010), F1462–F1472.
49. Feldman, A.M., Neprilysin inhibition in the time of precision medicine. JACC Heart Fail 4 (2016), 409–414.
50. Filippakopoulos, P., Knapp, S., Targeting bromodomains: Epigenetic readers of lysine acetylation. Nat Rev Drug Discov 13 (2014), 337–356.
51. Filippatos, G., Anker, S.D., Böhm, M., Gheorghiade, M., Kober, L., Krum, H.,.. Pitt, B., A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 37 (2016), 2105–2114.
52. Follath, F., Cleland, J.G., Just, H., Papp, J.G., Scholz, H., Peuhkurinen, K.,.. Lehtonen, L., Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet 360 (2002), 196–202.
53. Fox, K., Ford, I., Steg, P.G., Tendera, M., Ferrari, R., Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial. Lancet 372 (2008), 807–816.
54. Fox, K., Ford, I., Steg, P.G., Tendera, M., Robertson, M., Ferrari, R., Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A subgroup analysis of a randomised controlled trial. Lancet 372 (2008), 817–821.
55. Fox, K., Ford, I., Steg, P.G., Tardif, J.C., Tendera, M., Ferrari, R., Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 371 (2014), 1091–1099.
56. Fraccarollo, D., Berger, S., Galuppo, P., Kneitz, S., Hein, L., Schutz, G.,.. Bauersachs, J., Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 123 (2011), 400–408.
57. Francis, S.H., Busch, J.L., Corbin, J.D., Sibley, D., cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 62 (2010), 525–563.
58. Franco, F., Thomas, G.D., Giroir, B., Bryant, D., Bullock, M.C., Chwialkowski, M.C.,.. Peshock, R.M., Magnetic resonance imaging and invasive evaluation of development of heart failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 99 (1999), 448–454.
59. Gheorghiade, M., Greene, S.J., Butler, J., Filippatos, G., Lam, C.S., Maggioni, A.P.,.. Pieske, B., Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED Randomized Trial. JAMA 314 (2015), 2251–2262.
60. Giacca, M., Zacchigna, S., Harnessing the microRNA pathway for cardiac regeneration. J Mol Cell Cardiol 89 (2015), 68–74.
61. Gilsbach, R., Preissl, S., Gruning, B.A., Schnick, T., Burger, L., Benes, V.,.. Hein, L., Dynamic DNA methylation orchestrates cardiomyocyte development, maturation and disease. Nat Commun, 5, 2014, 5288.
62. Goedert, M., Neurodegeneration. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Abeta, tau, and alpha-synuclein. Science, 349, 2015, 1255555.
63. Granger, C.B., McMurray, J.J., Yusuf, S., Held, P., Michelson, E.L., Olofsson, B.,.. Swedberg, K., Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 362 (2003), 772–776.
64. Greenberg, B.H., Chou, W., Saikali, K.G., Escandon, R., Lee, J.H., Chen, M.M.,.. Shaburishvili, T., Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. JACC Heart Fail 3 (2015), 22–29.
65. Greenberg, B., Butler, J., Felker, G.M., Ponikowski, P., Voors, A.A., Desai, A.S.,.. Zsebo, K.M., Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): A randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet 387 (2016), 1178–1186.
66. Grossmann, C., Ruhs, S., Langenbruch, L., Mildenberger, S., Stratz, N., Schumann, K., Gekle, M., Nuclear shuttling precedes dimerization in mineralocorticoid receptor signaling. Chem Biol 19 (2012), 742–751.
67. Gu, J., Noe, A., Chandra, P., Al-Fayoumi, S., Ligueros-Saylan, M., Sarangapani, R.,.. Dole, W.P., Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 50 (2010), 401–414.
68. Gulick, T., Chung, M.K., Pieper, S.J., Lange, L.G., Schreiner, G.F., Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci U S A 86 (1989), 6753–6757.
69. Haas, J., Frese, K.S., Park, Y.J., Keller, A., Vogel, B., Lindroth, A.M.,.. Meder, B., Alterations in cardiac DNA methylation in human dilated cardiomyopathy. EMBO Mol Med 5 (2013), 413–429.
70. Haikala, H., Kaivola, J., Nissinen, E., Wall, P., Levijoki, J., Linden, I.B., Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 27 (1995), 1859–1866.
71. Harada, M., Luo, X., Murohara, T., Yang, B., Dobrev, D., Nattel, S., MicroRNA regulation and cardiac calcium signaling: Role in cardiac disease and therapeutic potential. Circ Res 114 (2014), 689–705.
72. Hayashidani, S., Tsutsui, H., Shiomi, T., Suematsu, N., Kinugawa, S., Ide, T.,.. Takeshita, A., Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105 (2002), 868–873.
73. Heusch, G., Libby, P., Gersh, B., Yellon, D., Bohm, M., Lopaschuk, G., Opie, L., Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383 (2014), 1933–1943.
74. Hohl, M., Wagner, M., Reil, J.C., Muller, S.A., Tauchnitz, M., Zimmer, A.M.,.. Maack, C., HDAC4 controls histone methylation in response to elevated cardiac load. J Clin Invest 123 (2013), 1359–1370.
75. Holtwick, R., van Eickels, M., Skryabin, B.V., Baba, H.A., Bubikat, A., Begrow, F.,.. Kuhn, M., Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 111 (2003), 1399–1407.
76. Iwata, N., Tsubuki, S., Takaki, Y., Watanabe, K., Sekiguchi, M., Hosoki, E.,.. Saido, T.C., Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nat Med 6 (2000), 143–150.
77. Iwata, N., Tsubuki, S., Takaki, Y., Shirotani, K., Lu, B., Gerard, N.P.,.. Saido, T.C., Metabolic regulation of brain Abeta by neprilysin. Science 292 (2001), 1550–1552.
78. Janssen, H.L., Reesink, H.W., Lawitz, E.J., Zeuzem, S., Rodriguez-Torres, M., Patel, K.,.. Hodges, M.R., Treatment of HCV infection by targeting microRNA. N Engl J Med 368 (2013), 1685–1694.
79. Jessup, M., Greenberg, B., Mancini, D., Cappola, T., Pauly, D.F., Jaski, B.,.. Hajjar, R.J., Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2 +-ATPase in patients with advanced heart failure. Circulation 124 (2011), 304–313.
80. Jonas, S., Izaurralde, E., Towards a molecular understanding of microRNA-mediated gene silencing. Nat Rev Genet 16 (2015), 421–433.
81. Jones, P.A., Functions of DNA methylation: Islands, start sites, gene bodies and beyond. Nat Rev Genet 13 (2012), 484–492.
82. Kadokami, T., Frye, C., Lemster, B., Wagner, C.L., Feldman, A.M., McTiernan, C.F., Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model. Circulation 104 (2001), 1094–1097.
83. Kang, S.H., Seok, Y.M., Song, M.J., Lee, H.A., Kurz, T., Kim, I., Histone deacetylase inhibition attenuates cardiac hypertrophy and fibrosis through acetylation of mineralocorticoid receptor in spontaneously hypertensive rats. Mol Pharmacol 87 (2015), 782–791.
84. Kao, Y.H., Liou, J.P., Chung, C.C., Lien, G.S., Kuo, C.C., Chen, S.A., Chen, Y.J., Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure. Int J Cardiol 168 (2013), 4178–4183.
85. Kass, D.A., Rescuing a failing heart: Putting on the squeeze. Nat Med 15 (2009), 24–25.
86. Kawase, Y., Ly, H.Q., Prunier, F., Lebeche, D., Shi, Y., Jin, H.,.. Hajjar, R.J., Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 51 (2008), 1112–1119.
87. Kee, H.J., Kook, H., Kruppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy. J Mol Cell Cardiol 47 (2009), 770–780.
88. Kim, K.H., Kim, H.K., Hwang, I.C., Cho, H.J., Je, N., Kwon, O.M.,.. Sohn, D.W., PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction: A 12-week, randomized, double-blind, placebo-controlled trial. Am Heart J 169 (2015), 813–822, e813.
89. Kjekshus, J., Gullestad, L., Heart rate as a therapeutic target in heart failure. Eur Heart J Suppl 1999:Suppl. H (1999), H64–H69.
90. Kjekshus, J., Apetrei, E., Barrios, V., Bohm, M., Cleland, J.G., Cornel, J.H.,.. Wikstrand, J., Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357 (2007), 2248–2261.
91. Koch, W.J., Rockman, H.A., Samama, P., Hamilton, R.A., Bond, R.A., Milano, C.A., Lefkowitz, R.J., Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science 268 (1995), 1350–1353.
92. Kolkhof, P., Delbeck, M., Kretschmer, A., Steinke, W., Hartmann, E., Barfacker, L.,.. Schafer, S., Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 64 (2014), 69–78.
93. Kong, Y., Tannous, P., Lu, G., Berenji, K., Rothermel, B.A., Olson, E.N., Hill, J.A., Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 113 (2006), 2579–2588.
94. Kuhn, M., Molecular physiology of membrane guanylyl cyclase receptors. Physiol Rev 96 (2016), 751–804.
95. Kumarswamy, R., Thum, T., Non-coding RNAs in cardiac remodeling and heart failure. Circ Res 113 (2013), 676–689.
96. Kusaka, H., Sueta, D., Koibuchi, N., Hasegawa, Y., Nakagawa, T., Lin, B.,.. Kim-Mitsuyama, S., LCZ696, angiotensin II receptor-neprilysin inhibitor, ameliorates high-salt-induced hypertension and cardiovascular injury more than valsartan alone. Am J Hypertens 28 (2015), 1409–1417.
97. Lainscak, M., Pelliccia, F., Rosano, G., Vitale, C., Schiariti, M., Greco, C.,.. Gaudio, C., Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. Int J Cardiol 200 (2015), 25–29.
98. Landmesser, U., Engberding, N., Bahlmann, F.H., Schaefer, A., Wiencke, A., Heineke, A.,.. Drexler, H., Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110 (2004), 1933–1939.
99. Langenickel, T.H., Tsubouchi, C., Ayalasomayajula, S., Pal, P., Valentin, M.A., Hinder, M.,.. Rajman, I., The effect of LCZ696 (sacubitril/valsartan) on amyloid-beta concentrations in cerebrospinal fluid in healthy subjects. Br J Clin Pharmacol 81 (2016), 878–890.
100. Lavall, D., Selzer, C., Schuster, P., Lenski, M., Adam, O., Schafers, H.J.,.. Laufs, U., The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem 289 (2014), 6656–6668.
101. Lea, W.B., Kwak, E.S., Luther, J.M., Fowler, S.M., Wang, Z., Ma, J.,.. Brown, N.J., Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 75 (2009), 936–944.
102. Lee, H.A., Lee, D.Y., Cho, H.M., Kim, S.Y., Iwasaki, Y., Kim, I.K., Histone deacetylase inhibition attenuates transcriptional activity of mineralocorticoid receptor through its acetylation and prevents development of hypertension. Circ Res 112 (2013), 1004–1012.
103. Lewis, G.D., Lachmann, J., Camuso, J., Lepore, J.J., Shin, J., Martinovic, M.E.,.. Semigran, M.J., Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 115 (2007), 59–66.
104. Li, C., Zhang, Y.Y., Frieler, R.A., Zheng, X.J., Zhang, W.C., Sun, X.N.,.. Mortensen, R.M., Myeloid mineralocorticoid receptor deficiency inhibits aortic constriction-induced cardiac hypertrophy in mice. PLoS One, 9, 2014, e110950.
105. Li, Y., Wang, J., Zhang, S., Liu, Z., Neprilysin gene transfer: A promising therapeutic approach for Alzheimer's disease. J Neurosci Res 93 (2015), 1325–1329.
106. Logeart, D., Vinet, L., Ragot, T., Heimburger, M., Louedec, L., Michel, J.B.,.. Mercadier, J.J., Percutaneous intracoronary delivery of SERCA gene increases myocardial function: A tissue Doppler imaging echocardiographic study. Am J Physiol Heart Circ Physiol 291 (2006), H1773–H1779.
107. Lother, A., Hein, L., Vascular mineralocorticoid receptors: Linking risk factors, hypertension, and heart disease. Hypertension 68 (2016), 6–10.
108. Lother, A., Berger, S., Gilsbach, R., Rosner, S., Ecke, A., Barreto, F.,.. Hein, L., Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension 57 (2011), 746–754.
109. Lother, A., Moser, M., Bode, C., Feldman, R.D., Hein, L., Mineralocorticoids in the heart and vasculature: New insights for old hormones. Annu Rev Pharmacol Toxicol 55 (2015), 289–312.
110. Lother, A., Furst, D., Bergemann, S., Gilsbach, R., Grahammer, F., Huber, T.B.,.. Hein, L., Deoxycorticosterone acetate/salt-induced cardiac but not renal injury is mediated by endothelial mineralocorticoid receptors independently from blood pressure. Hypertension 67 (2016), 130–138.
111. Lu, Z., Xu, X., Hu, X., Lee, S., Traverse, J.H., Zhu, G.,.. Chen, Y., Oxidative stress regulates left ventricular PDE5 expression in the failing heart. Circulation 121 (2010), 1474–1483.
112. Luo, M., Anderson, M.E., Mechanisms of altered Ca(2)(+) handling in heart failure. Circ Res 113 (2013), 690–708.
113. Ma, F.Y., Han, Y., Nikolic-Paterson, D.J., Kolkhof, P., Tesch, G.H., Suppression of rapidly progressive mouse glomerulonephritis with the non-steroidal mineralocorticoid receptor antagonist BR-4628. PLoS One, 10, 2015, e0145666.
114. Maggioni, A.P., Anand, I., Gottlieb, S.O., Latini, R., Tognoni, G., Cohn, J.N., Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol 40 (2002), 1414–1421.
115. Malik, F.I., Hartman, J.J., Elias, K.A., Morgan, B.P., Rodriguez, H., Brejc, K.,.. Morgans, D.J., Cardiac myosin activation: A potential therapeutic approach for systolic heart failure. Science 331 (2011), 1439–1443.
116. Mann, D.L., Innate immunity and the failing heart: The cytokine hypothesis revisited. Circ Res 116 (2015), 1254–1268.
117. Mann, D.L., McMurray, J.J., Packer, M., Swedberg, K., Borer, J.S., Colucci, W.S.,.. Fleming, T., Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004), 1594–1602.
118. Manz, M., Reuter, M., Lauck, G., Omran, H., Jung, W., A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology 100 (2003), 149–155.
119. Marks, A.R., Calcium cycling proteins and heart failure: Mechanisms and therapeutics. J Clin Invest 123 (2013), 46–52.
120. Mathiyalagan, P., Okabe, J., Chang, L., Su, Y., Du, X.J., El-Osta, A., The primary microRNA-208b interacts with polycomb-group protein, Ezh2, to regulate gene expression in the heart. Nucleic Acids Res 42 (2014), 790–803.
121. Mayer, S.C., Gilsbach, R., Preissl, S., Monroy Ordonez, E.B., Schnick, T., Beetz, N.,.. Hein, L., Adrenergic repression of the epigenetic reader MeCP2 facilitates cardiac adaptation in chronic heart failure. Circ Res 117 (2015), 622–633.
122. McKinsey, T.A., Therapeutic potential for HDAC inhibitors in the heart. Annu Rev Pharmacol Toxicol 52 (2012), 303–319.
123. McMurray, J.J., It is BEAUTIFUL we should be concerned about, not SIGNIFY: Is ivabradine less effective in ischaemic compared with non-ischaemic LVSD?. Eur Heart J 36 (2015), 2047–2049.
124. McMurray, J.J., Neprilysin inhibition to treat heart failure: A tale of science, serendipity, and second chances. Eur J Heart Fail 17 (2015), 242–247.
125. McMurray, J.J., Packer, M., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R.,.. Zile, M.R., Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.
126. Mebazaa, A., Nieminen, M.S., Packer, M., Cohen-Solal, A., Kleber, F.X., Pocock, S.J.,.. Kivikko, M., Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE Randomized Trial. JAMA 297 (2007), 1883–1891.
127. MERIT-HF, Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999), 2001–2007.
128. Miyamoto, M.I., del Monte, F., Schmidt, U., DiSalvo, T.S., Kang, Z.B., Matsui, T.,.. Hajjar, R.J., Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A 97 (2000), 793–798.
129. Molkentin, J.D., Dorn, G.W. II, Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 63 (2001), 391–426.
130. Montgomery, R.L., Hullinger, T.G., Semus, H.M., Dickinson, B.A., Seto, A.G., Lynch, J.M.,.. van Rooij, E., Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124 (2011), 1537–1547.
131. Movassagh, M., Choy, M.K., Knowles, D.A., Cordeddu, L., Haider, S., Down, T.,.. Foo, R.S., Distinct epigenomic features in end-stage failing human hearts. Circulation 124 (2011), 2411–2422.
132. Mulder, P., Barbier, S., Chagraoui, A., Richard, V., Henry, J.P., Lallemand, F.,.. Thuillez, C., Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation 109 (2004), 1674–1679.
133. Mulder, P., Mellin, V., Favre, J., Vercauteren, M., Remy-Jouet, I., Monteil, C.,.. Thuillez, C., Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: A comparison with spironolactone. Eur Heart J 29 (2008), 2171–2179.
134. Nuhrenberg, T., Gilsbach, R., Preissl, S., Schnick, T., Hein, L., Epigenetics in cardiac development, function, and disease. Cell Tissue Res 356 (2014), 585–600.
135. Ohno-Matsui, K., Parallel findings in age-related macular degeneration and Alzheimer's disease. Prog Retin Eye Res 30 (2011), 217–238.
136. Orstavik, O., Manfra, O., Andressen, K.W., Andersen, G.O., Skomedal, T., Osnes, J.B.,.. Krobert, K.A., The inotropic effect of the active metabolite of levosimendan, OR-1896, is mediated through inhibition of PDE3 in rat ventricular myocardium. PLoS One, 10, 2015, e0115547.
137. Packer, M., Fowler, M.B., Roecker, E.B., Coats, A.J., Katus, H.A., Krum, H.,.. DeMets, D.L., Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106 (2002), 2194–2199.
138. Packer, M., McMurray, J.J., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R.,.. Wong, R.C., Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131 (2015), 54–61.
139. Pandey, A., Garg, S., Matulevicius, S.A., Shah, A.M., Garg, J., Drazner, M.H.,.. Kumbhani, D.J., Effect of mineralocorticoid receptor antagonists on cardiac structure and function in patients with diastolic dysfunction and heart failure with preserved ejection fraction: A meta-analysis and systematic review. J Am Heart Assoc, 4, 2015, e002137.
140. Patel, J.B., Valencik, M.L., Pritchett, A.M., Burnett, J.C. Jr., McDonald, J.A., Redfield, M.M., Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol 289 (2005), H777–H784.
141. Patrick, D.M., Montgomery, R.L., Qi, X., Obad, S., Kauppinen, S., Hill, J.A.,.. Olson, E.N., Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest 120 (2010), 3912–3916.
142. Patrucco, E., Domes, K., Sbroggio, M., Blaich, A., Schlossmann, J., Desch, M.,.. Hofmann, F., Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis. Proc Natl Acad Sci U S A 111 (2014), 12925–12929.
143. Paulus, W.J., Tschope, C., A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62 (2013), 263–271.
144. Pfeffer, M.A., McMurray, J.J., Velazquez, E.J., Rouleau, J.L., Kober, L., Maggioni, A.P.,.. Califf, R.M., Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003), 1893–1906.
145. Pfeffer, M.A., Claggett, B., Assmann, S.F., Boineau, R., Anand, I.S., Clausell, N.,.. Pitt, B., Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131 (2015), 34–42.
146. Pieske, B., Butler, J., Filippatos, G., Lam, C., Maggioni, A.P., Ponikowski, P.,.. Gheorghiade, M., Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail 16 (2014), 1026–1038.
147. Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A.,.. Wittes, J., The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999), 709–717.
148. Pitt, B., Kober, L., Ponikowski, P., Gheorghiade, M., Filippatos, G., Krum, H.,.. Zannad, F., Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial. Eur Heart J 34 (2013), 2453–2463.
149. Pitt, B., Pfeffer, M.A., Assmann, S.F., Boineau, R., Anand, I.S., Claggett, B.,.. McKinlay, S.M., Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 (2014), 1383–1392.
150. Pittet, M.J., Nahrendorf, M., Swirski, F.K., The journey from stem cell to macrophage. Ann N Y Acad Sci 1319 (2014), 1–18.
151. Pleger, S.T., Shan, C., Ksienzyk, J., Bekeredjian, R., Boekstegers, P., Hinkel, R.,.. Most, P., Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci Transl Med, 3, 2011, 92ra64.
152. Pleger, S.T., Brinks, H., Ritterhoff, J., Raake, P., Koch, W.J., Katus, H.A., Most, P., Heart failure gene therapy: The path to clinical practice. Circ Res 113 (2013), 792–809.
153. Pokreisz, P., Vandenwijngaert, S., Bito, V., Van den Bergh, A., Lenaerts, I., Busch, C.,.. Janssens, S.P., Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 119 (2009), 408–416.
154. Ponikowski, P., Voors, A.A., Anker, S.D., Bueno, H., Cleland, J.G., Coats, A.J.,.. van der Meer, P., 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 (2016), 2129–2200.
155. Pradhan, K., Sydykov, A., Tian, X., Mamazhakypov, A., Neupane, B., Luitel, H.,.. Schermuly, R.T., Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice. Int J Cardiol 216 (2016), 85–91.
156. Raake, P.W., Vinge, L.E., Gao, E., Boucher, M., Rengo, G., Chen, X.,.. Koch, W.J., G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure. Circ Res 103 (2008), 413–422.
157. Raake, P.W., Schlegel, P., Ksienzyk, J., Reinkober, J., Barthelmes, J., Schinkel, S.,.. Muller, O.J., AAV6.betaARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur Heart J 34 (2013), 1437–1447.
158. Ragueneau, I., Laveille, C., Jochemsen, R., Resplandy, G., Funck-Brentano, C., Jaillon, P., Pharmacokinetic–pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther 64 (1998), 192–203.
159. Redfield, M.M., Chen, H.H., Borlaug, B.A., Semigran, M.J., Lee, K.L., Lewis, G.,.. Braunwald, E., Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial. JAMA 309 (2013), 1268–1277.
160. Reil, J.C., Hohl, M., Reil, G.H., Granzier, H.L., Kratz, M.T., Kazakov, A.,.. Bohm, M., Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur Heart J 34 (2013), 2839–2849.
161. Renaud, L., Harris, L.G., Mani, S.K., Kasiganesan, H., Chou, J.C., Baicu, C.F.,.. Menick, D.R., HDACs regulate miR-133a expression in pressure overload-induced cardiac fibrosis. Circ Heart Fail 8 (2015), 1094–1104.
162. Rengo, G., Lymperopoulos, A., Leosco, D., Koch, W.J., GRK2 as a novel gene therapy target in heart failure. J Mol Cell Cardiol 50 (2011), 785–792.
163. Ritchie, R.H., Irvine, J.C., Rosenkranz, A.C., Patel, R., Wendt, I.R., Horowitz, J.D., Kemp-Harper, B.K., Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO* and beyond. Pharmacol Ther 124 (2009), 279–300.
164. Rockman, H.A., Choi, D.J., Akhter, S.A., Jaber, M., Giros, B., Lefkowitz, R.J.,.. Koch, W.J., Control of myocardial contractile function by the level of beta-adrenergic receptor kinase 1 in gene-targeted mice. J Biol Chem 273 (1998), 18180–18184.
165. Roger, V.L., Epidemiology of heart failure. Circ Res 113 (2013), 646–659.
166. Ruilope, L.M., Dukat, A., Bohm, M., Lacourciere, Y., Gong, J., Lefkowitz, M.P., Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study. Lancet 375 (2010), 1255–1266.
167. Schmid, E., Neef, S., Berlin, C., Tomasovic, A., Kahlert, K., Nordbeck, P.,.. Lorenz, K., Cardiac RKIP induces a beneficial beta-adrenoceptor-dependent positive inotropy. Nat Med 21 (2015), 1298–1306.
168. Schubeler, D., Function and information content of DNA methylation. Nature 517 (2015), 321–326.
169. Schupp, N., Kolkhof, P., Queisser, N., Gartner, S., Schmid, U., Kretschmer, A.,.. Stopper, H., Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats. FASEB J 25 (2011), 968–978.
170. Solomon, S.D., Zile, M., Pieske, B., Voors, A., Shah, A., Kraigher-Krainer, E.,.. McMurray, J.J., The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial. Lancet 380 (2012), 1387–1395.
171. SOLVD, Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 325 (1991), 293–302.
172. SOLVD, Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 327 (1992), 685–691.
173. Spiltoir, J.I., Stratton, M.S., Cavasin, M.A., Demos-Davies, K., Reid, B.G., Qi, J.,.. McKinsey, T.A., BET acetyl-lysine binding proteins control pathological cardiac hypertrophy. J Mol Cell Cardiol 63 (2013), 175–179.
174. Stenzig, J., Hirt, M.N., Loser, A., Bartholdt, L.M., Hensel, J.T., Werner, T.R.,.. Eschenhagen, T., DNA methylation in an engineered heart tissue model of cardiac hypertrophy: Common signatures and effects of DNA methylation inhibitors. Basic Res Cardiol, 111, 2016, 9.
175. Suckau, L., Fechner, H., Chemaly, E., Krohn, S., Hadri, L., Kockskamper, J.,.. Poller, W.C., Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 119 (2009), 1241–1252.
176. Swedberg, K., Komajda, M., Bohm, M., Borer, J.S., Ford, I., Dubost-Brama, A.,.. Tavazzi, L., Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 376 (2010), 875–885.
177. Swedberg, K., Komajda, M., Bohm, M., Borer, J., Robertson, M., Tavazzi, L., Ford, I., Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: Is there an influence of beta-blocker dose? Findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol 59 (2012), 1938–1945.
178. Swirski, F.K., Nahrendorf, M., Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 339 (2013), 161–166.
179. Tavazzi, L., Maggioni, A.P., Marchioli, R., Barlera, S., Franzosi, M.G., Latini, R.,.. Tognoni, G., Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 372 (2008), 1231–1239.
180. Teerlink, J.R., Clarke, C.P., Saikali, K.G., Lee, J.H., Chen, M.M., Escandon, R.D.,.. Wolff, A.A., Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: A first-in-man study. Lancet 378 (2011), 667–675.
181. Teerlink, J.R., Felker, G.M., McMurray, J.V., Solomon, S.D., Monsalvo, M.L., Legg, J.,.. Honarpour, N., Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): Final results from a double-blind, randomized, placebo-controlled, multicenter study. Circulation 132 (2015), 2267–2285.
182. Teerlink, J.R., Felker, G.M., McMurray, J.J., Ponikowski, P., Metra, M., Filippatos, G.S.,.. Wasserman, S.M., Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. J Am Coll Cardiol 67 (2016), 1444–1455.
183. Thal, D.M., Homan, K.T., Chen, J., Wu, E.K., Hinkle, P.M., Huang, Z.M.,.. Tesmer, J.J., Paroxetine is a direct inhibitor of G protein-coupled receptor kinase 2 and increases myocardial contractility. ACS Chem Biol 7 (2012), 1830–1839.
184. Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M.,.. Engelhardt, S., MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456 (2008), 980–984.
185. Thum, T., Chau, N., Bhat, B., Gupta, S.K., Linsley, P.S., Bauersachs, J., Engelhardt, S., Comparison of different miR-21 inhibitor chemistries in a cardiac disease model. J Clin Invest 121 (2011), 461–462 (author reply 462-463).
186. Toldo, S., Mezzaroma, E., Bressi, E., Marchetti, C., Carbone, S., Sonnino, C.,.. Abbate, A., Interleukin-1beta blockade improves left ventricular systolic/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse. J Cardiovasc Pharmacol 64 (2014), 1–6.
187. Toldo, S., Mezzaroma, E., O'Brien, L., Marchetti, C., Seropian, I.M., Voelkel, N.F.,.. Abbate, A., Interleukin-18 mediates interleukin-1-induced cardiac dysfunction. Am J Physiol Heart Circ Physiol 306 (2014), H1025–H1031.
188. Ucar, A., Gupta, S.K., Fiedler, J., Erikci, E., Kardasinski, M., Batkai, S.,.. Thum, T., The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun, 3, 2012, 1078.
189. Usher, M.G., Duan, S.Z., Ivaschenko, C.Y., Frieler, R.A., Berger, S., Schutz, G.,.. Mortensen, R.M., Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 120 (2010), 3350–3364.
190. van Rooij, E., Sutherland, L.B., Qi, X., Richardson, J.A., Hill, J., Olson, E.N., Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316 (2007), 575–579.
191. Van Tassell, B.W., Arena, R.A., Toldo, S., Mezzaroma, E., Azam, T., Seropian, I.M.,.. Abbate, A., Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One, 7, 2012, e33438.
192. Van Tassell, B.W., Arena, R., Biondi-Zoccai, G., McNair Canada, J., Oddi, C., Abouzaki, N.A.,.. Abbate, A., Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol 113 (2014), 321–327.
193. Venkatesh, S., Workman, J.L., Histone exchange, chromatin structure and the regulation of transcription. Nat Rev Mol Cell Biol 16 (2015), 178–189.
194. Volterrani, M., Cice, G., Caminiti, G., Vitale, C., D'Isa, S., Perrone Filardi, P.,.. Rosano, G.M., Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol 151 (2011), 218–224.
195. von Lueder, T.G., Atar, D., Krum, H., Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther 144 (2014), 41–49.
196. von Lueder, T.G., Wang, B.H., Kompa, A.R., Huang, L., Webb, R., Jordaan, P.,.. Krum, H., Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail 8 (2015), 71–78.
197. Wahlquist, C., Jeong, D., Rojas-Munoz, A., Kho, C., Lee, A., Mitsuyama, S.,.. Mercola, M., Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 508 (2014), 531–535.
198. Xu, X., Tan, X., Tampe, B., Nyamsuren, G., Liu, X., Maier, L.S.,.. Zeisberg, E.M., Epigenetic balance of aberrant Rasal1 promoter methylation and hydroxymethylation regulates cardiac fibrosis. Cardiovasc Res 105 (2015), 279–291.
199. Yan, C., Miller, C.L., Abe, J., Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res 100 (2007), 489–501.
200. Yan, M., Chen, C., Gong, W., Yin, Z., Zhou, L., Chaugai, S., Wang, D.W., miR-21-3p regulates cardiac hypertrophic response by targeting histone deacetylase-8. Cardiovasc Res 105 (2015), 340–352.
201. Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E. Jr., Colvin, M.M.,.. Westlake, C., 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: An update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 2016, 10.1161/CIR.0000000000000435.
202. Zannad, F., McMurray, J.J., Krum, H., van Veldhuisen, D.J., Swedberg, K., Shi, H.,.. Pitt, B., Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364 (2011), 11–21.
203. Zhang, Q.J., Chen, H.Z., Wang, L., Liu, D.P., Hill, J.A., Liu, Z.P., The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice. J Clin Invest 121 (2011), 2447–2456.
204. Zhuang, X.D., Long, M., Li, F., Hu, X., Liao, X.X., Du, Z.M., PDE5 inhibitor sildenafil in the treatment of heart failure: A meta-analysis of randomized controlled trials. Int J Cardiol 172 (2014), 581–587.
205. Zsebo, K., Yaroshinsky, A., Rudy, J.J., Wagner, K., Greenberg, B., Jessup, M., Hajjar, R.J., Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: Analysis of recurrent cardiovascular events and mortality. Circ Res 114 (2014), 101–108.